Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October

Date : 09/27/2018 @ 7:00AM
Source : GlobeNewswire
Stock : Immunomedics, Inc. (IMMU)
Quote : 15.55  -0.28 (-1.77%) @ 3:30PM

Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October

Press Release

27 September 2018

Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October

Immunicum AB (publ; IMMU.ST) today announced that Company leadership will present at upcoming regulatory affairs, industry and scientific conferences in October.

The Organization for Professionals in Regulatory Affairs (TOPRA) Annual Symposium 2018 -Human Medicines Section
Date: October 1 - 3, 2018
Presentation Time: October 3, 12:00 pm Central European Time
Presentation Title: An SME regulatory ATMP case study
Presenter: Margareth Jorvid, Head of Regulatory and QA
Venue: Quality Hotel Globe, Stockholm, Sweden

Sachs 18th Annual Biotech in Europe Forum
Date: October 4 - 5, 2018
Presentation Time: October 5, 2018, 10:15 am Central European Time
Presentation Title: Company Overivew
Panel: Oncology I - BD&L Panel Friday, October 5, 11:15 am Central European Time
Presenter and Panelist: Carlos de Sousa, CEO
Venue: Congress Center Basel, Switzerland

ESMO 2018 Congress
Date: October 19 - 23, 2018
Poster Presentation Time: October 22, 2018, 12:45 pm - 1:45 pm Central European Time
Poster No. and Title: 440P; Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect
Presenter: Alex Karlsson-Parra, CSO
Venue: Messe Munich, Munich, Germany

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75

Media Relations

Gretchen Schweitzer and Jacob Verghese
Trophic Communications
Telephone: +49 172 861 8540

  About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm

20180927_Immunicum_October Conferences_ENG_Final

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Immunomedics (NASDAQ:IMMU)
Historical Stock Chart

1 Year : From May 2018 to May 2019

Click Here for more Immunomedics Charts.

Immunomedics (NASDAQ:IMMU)
Intraday Stock Chart

Today : Wednesday 22 May 2019

Click Here for more Immunomedics Charts.

Latest IMMU Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.